Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.

@article{Kosaraju2013VildagliptinAA,
  title={Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease.},
  author={Jayasankar Kosaraju and Vishakantha Murthy and Rizwan Basha Khatwal and Anil Dubala and Santhivardhan Chinni and Satish Kumar Muthureddy Nataraj and Duraiswamy Basavan},
  journal={The Journal of pharmacy and pharmacology},
  year={2013},
  volume={65 12},
  pages={1773-84}
}
OBJECTIVES Adults who develop type 2 diabetes (T2D) at later stages are at a higher risk of developing Alzheimer's disease (AD). Pharmacological agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors that increase the levels of glucagon-like peptide-1 (GLP-1) and ameliorate T2D have also become promising candidates as disease-modifying agents in the treatment of AD. The present study investigates the efficacy of vildagliptin, a DPP-4 inhibitor in a streptozotocin (STZ)-induced rat model of AD… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Alzhei - mer ’ s disease facts and figures

  • T Hamaguchi
  • Alzheimers Dement
  • 2012

Similar Papers

Loading similar papers…